WASHINGTON - The Centers for Medicare & Medicaid Services (CMS) plans to convene an advisory panel next March to provide input on establishing a national coverage decision (NCD) for the use of anemia drugs, such as Amgen Inc.'s Epogen (epoetin alfa) and Centocor Ortho Biotech Product LP's Procrit (epoetin alfa), in patients with chronic kidney disease (CKD). (BioWorld Today) Read More
